What is the elimination half‑life of quetiapine (Seroquel)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Seroquel Half-Life

The elimination half-life of quetiapine (Seroquel) is approximately 6 hours in adults at therapeutic doses 1.

Key Pharmacokinetic Details

According to the FDA label, quetiapine demonstrates the following elimination characteristics 1:

  • Mean terminal half-life: ~6 hours within the proposed clinical dose range in adults
  • Steady-state achievement: 2 days of dosing
  • Time to peak concentration (Tmax): 1.5 hours after oral administration
  • Primary elimination route: Hepatic metabolism via CYP3A4

Age-Related Variations

Pediatric Patients (10-17 years)

The mean quetiapine half-life is approximately 6 hours, similar to adults 2. Pharmacokinetic profiles in children aged 10 years and older are comparable to adults, suggesting no dosage adjustment is required based on age alone 2.

Elderly Patients (≥65 years)

Oral clearance is reduced by 40% compared to younger patients, which may effectively prolong the half-life 1. Dosing adjustment is necessary in this population.

Clinical Context: Half-Life in Overdose

Important caveat: In acute quetiapine intoxication, the typical half-life extends to approximately 16.5 hours—significantly longer than therapeutic doses 3. This prolonged elimination in overdose situations is critical for managing toxicity and monitoring duration.

Special Populations

  • Renal impairment: 25% lower mean oral clearance in severe renal impairment, but this has minimal impact on half-life 1
  • Hepatic impairment: May reduce clearance and effectively prolong half-life 1
  • No effect from: Gender, race, or smoking status 1

Receptor Occupancy vs. Plasma Half-Life

Research demonstrates a disconnect between plasma half-life and clinical effect 4. While plasma half-life is ~6 hours, dopamine D2 receptor occupancy half-life is approximately 10 hours, and serotonin 5HT2 receptor blockade persists even longer with a half-life of 27 hours 4. This pharmacodynamic profile supports twice-daily dosing despite the relatively short plasma half-life.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.